Ignite Creation Date:
2025-12-24 @ 4:08 PM
Ignite Modification Date:
2026-05-29 @ 6:06 AM
Study NCT ID:
NCT04807166
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-07-03
First Post:
2021-03-15
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer
Sponsor:
Wenjun Cheng
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
JiangsuCHENG001
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None